INO · Inovio Pharmaceuticals, Inc.
$1.09
+0.19 (+21.10%)
At close · Aug 14
View the 10-K filed Mar 12, 2026
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”View the 10-Q filed Aug 12, 2026
Customer concentration
— top customer 100% of revenue
One customer — 100% of revenue (the years ended December 31, 2025 and 2024)
“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
Market Cap
$112.70M
Shares
103.40M
Inovio Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Inovio Pharmaceuticals, Inc. (INO) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲3038.2%
$9.15M
−$37.78M
'22 Q3
22-11-08
▼85.1%
$124,666
−$54.46M
'22 Q4
23-03-01
▼42.3%
$114,943
−$40.65M
'23 Q1
23-05-10
▼71.2%
$225,971
−$35.53M
'23 Q2
23-08-09
▼95.8%
$388,446
−$33.93M
'23 Q3
23-11-09
▼17.7%
$102,650
−$25.00M
'23 Q4
24-03-06
▼55.4%
$100,762
−$32.24M
'24 Q2
24-08-08
▼100%
$
−$30.47M
'24 Q1
24-08-08
▼100%
$
−$25.17M
'24 Q3
24-11-14
▲14%
$116,994
−$19.38M
'24 Q4
25-03-18
·
$65,343
−$19.69M
'25 Q1
25-05-13
▼100%
$
−$23.52M
'25 Q2
25-08-12
·
$
−$45.50M
'25 Q3
25-11-10
▼100%
$
$3.76M
'25 Q4
26-03-12
▼100%
$
−$19.68M
'26 Q1
26-05-13
LATEST
·
$
−$6.01M
'26 Q2
26-08-12
Earnings call
FY26 · Q2
2026-08-12
INOVIO Second Quarter 2026 Financial Results Conference Call
Revenue
$
Diluted EPS
$-0.07
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
2026 Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-13
Inovio Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Positive tone
Accelerated Approval Eligibility / Unmet Need
INO3107 Regulatory Progress / BLA Review
FDA Regulatory Uncertainty
Revenue
$
▼ 100% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Inovio Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Positive tone
BLA review and accelerated approval eligibility for INO-3107
Differentiation vs. PAPZIMEOS competitor
Commercial launch preparation for RRP market
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Inovio Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
INO-3107 BLA submission and FDA review
DMAb platform technology
Commercial readiness and launch preparation
Revenue
$
Diluted EPS
$-0.87
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Inovio Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Clinical efficacy and long-term data for 3107
Confirmatory trial and IND update
Commercial launch preparation and pricing
Revenue
$
▼ 100% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Inovio Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Confident tone
BLA submission progress for INO-3107
Clinical data and durability
Earlier-stage pipeline (DMAbs)
Revenue
$65,343
Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Inovio Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Positive tone
INO-3107 BLA Submission and Regulatory Progress
Durability and Efficacy of 3107
CELLECTRA Device Manufacturing Issue Resolution
Revenue
$116,994*
▲ 14% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Inovio Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
INO-3107 lead candidate progress
Immune response and mechanism of action data
Regulatory engagement
Revenue
$
▼ 100% YoY Diluted EPS
$-0.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-08-08
Inovio Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Positive tone
INO-3107 BLA submission for RRP
Regulatory engagement (FDA and Europe)
Patient burden of RRP disease
Revenue
$
▼ 100% YoY Diluted EPS
$-1.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Inovio Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Positive tone
INO-3107 BLA submission and manufacturing issue
FDA pre-BLA meeting and regulatory progress
Redosing and confirmatory trial strategy
Revenue
$100,762
▼ 55.4% YoY Diluted EPS
$-1.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Inovio Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
Recurrent Respiratory Papillomatosis (RRP) disease burden
Immuno-oncology pipeline (3112, 5401)
INO-3107 BLA submission and approval pathway
Revenue
$102,650*
▼ 17.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Inovio Pharmaceuticals, Inc. Q3 FY2023 Earnings Call
Revenue
$388,446
▼ 95.8% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Inovio Pharmaceuticals, Inc. Q2 FY2023 Earnings Call
Revenue
$225,971
▼ 71.2% YoY Diluted EPS
$-1.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Inovio Pharmaceuticals, Inc. Q1 FY2023 Earnings Call
Revenue
$114,943
▼ 42.3% YoY Diluted EPS
$-1.89
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Inovio Pharmaceuticals, Inc. Q4 FY2022 Earnings Call
Revenue
$124,666*
▼ 85.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Inovio Pharmaceuticals, Inc. Q3 FY2022 Earnings Call
Revenue
$9.15M
▲ 3038.2% YoY Diluted EPS
$-1.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Inovio Pharmaceuticals, Inc. Q2 FY2022 Earnings Call
Revenue
$784,395
▲ 187.5% YoY Diluted EPS
$-5.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Inovio Pharmaceuticals, Inc. Q1 FY2022 Earnings Call
Revenue
$199,074
▼ 46.4% YoY Diluted EPS
$-4.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Inovio Pharmaceuticals, Inc. Q4 FY2021 Earnings Call
Revenue
$839,116*
▼ 85% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Inovio Pharmaceuticals, Inc. Q3 FY2021 Earnings Call
Revenue
$291,698
▲ 23.5% YoY Diluted EPS
$-3.48
▼ 363.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Inovio Pharmaceuticals, Inc. Q2 FY2021 Earnings Call
Revenue
$272,824
▲ 2.1% YoY Diluted EPS
$-4.68
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Inovio Pharmaceuticals, Inc. Q1 FY2021 Earnings Call
Revenue
$371,120
▼ 72% YoY Diluted EPS
$-3.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Inovio Pharmaceuticals, Inc. Q4 FY2020 Earnings Call
Revenue
$5.58M
▲ 1896.7% YoY Diluted EPS
$-1.68
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Inovio Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Revenue
$236,178
▼ 72.8% YoY Diluted EPS
$1.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Inovio Pharmaceuticals, Inc. Q2 FY2020 Earnings Call
Revenue
$267,187
▲ 96.9% YoY Diluted EPS
$-9.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Inovio Pharmaceuticals, Inc. Q1 FY2020 Earnings Call
Revenue
$1.33M
▼ 53.1% YoY Diluted EPS
$-3.12
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inovio Pharmaceuticals, Inc. Q4 FY2019 Earnings Call
Revenue
$279,488
▼ 88.8% YoY Diluted EPS
$-4.56
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1055726
CUSIP
45773H409
13F (30d)
103 filings
101 filers
Visit website
Investor relations